{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T19:57:40Z","timestamp":1789934260514,"version":"4.0.1"},"reference-count":217,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T00:00:00Z","timestamp":1572566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1016\/j.phrs.2019.104473","type":"journal-article","created":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T11:31:46Z","timestamp":1569929506000},"page":"104473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Biological and synthetic target DMARDs in psoriatic arthritis"],"prefix":"10.1016","volume":"149","author":[{"given":"Ettore","family":"Silvagni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Bortoluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Ciancio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Govoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.phrs.2019.104473_bib0005","doi-asserted-by":"crossref","first-page":"ii14","DOI":"10.1136\/ard.2004.032482","article-title":"Psoriatic arthritis: epidemiology, clinical features, course, and outcome","volume":"64","author":"Gladman","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0010","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","article-title":"The pathogenesis of psoriatic arthritis","volume":"391","author":"Veale","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.104473_bib0015","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/S0140-6736(18)30949-8","article-title":"Clinical management of psoriatic arthritis","volume":"391","author":"Van den Bosch","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.104473_bib0020","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(89)90430-3","article-title":"Inhibitory effect of tnf\u03b1 antibodies on synovial cell interleukin-1 production in rheumatoid arthritis","volume":"334","author":"Brennan","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.104473_bib0025","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/nm939","article-title":"TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases","volume":"9","author":"Feldmann","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2019.104473_bib0030","doi-asserted-by":"crossref","first-page":"R569","DOI":"10.1186\/ar1698","article-title":"Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis","volume":"7","author":"Kruithof","year":"2005","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2019.104473_bib0035","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/path.1758","article-title":"Differential expression and response to anti\u2010TNF\u03b1 treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis","volume":"206","author":"Rycke","year":"2005","journal-title":"J. Pathol."},{"key":"10.1016\/j.phrs.2019.104473_bib0040","doi-asserted-by":"crossref","first-page":"R74","DOI":"10.1186\/ar3796","article-title":"Intimal lining layer macrophages but not synovial sublining macrophages display an IL-10 polarized-like phenotype in chronic synovitis","volume":"14","author":"Ambarus","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2019.104473_bib0045","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1038\/nrrheum.2016.91","article-title":"Macrophage heterogeneity in the context of rheumatoid arthritis","volume":"12","author":"Udalova","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0050","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1186\/ar3228","article-title":"Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy - a single centre, open-label study","volume":"13","author":"Pontifex","year":"2011","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2019.104473_bib0055","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1136\/ard.2004.029751","article-title":"B on, Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis","volume":"64","author":"Haringman","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0060","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1136\/ard.2003.018085","article-title":"Early effects of tumour necrosis factor \u03b1 blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis","volume":"63","author":"Goedkoop","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0065","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1002\/art.21914","article-title":"OMERACT Special Interest Group on Synovial Analysis in Clinical Trials, Identification of synovial biomarkers of response to experimental treatment in early-phase clinical trials in spondylarthritis","volume":"54","author":"Kruithof","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104473_bib0070","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1002\/art.20181","article-title":"Antiangiogenic effects of anti\u2013tumor necrosis factor \u03b1 therapy with infliximab in psoriatic arthritis","volume":"50","author":"Ca\u00f1ete","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104473_bib0075","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/art.33396","article-title":"Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritis","volume":"64","author":"Noordenbos","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104473_bib0080","article-title":"IL-22-and GM-CSF-expressing but not IL-17A-expressing group 3 innate lymphoid cells are expanded in the inflamed spondyloarthritis joint","author":"Blijdorp","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0085","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.4049\/jimmunol.172.3.1935","volume":"172","author":"Curran","year":"2004","journal-title":"J. Immunol."},{"key":"10.1016\/j.phrs.2019.104473_bib0090","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11010-011-1036-6","article-title":"IL-17 receptor and its functional significance in psoriatic arthritis","volume":"359","author":"Raychaudhuri","year":"2012","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.phrs.2019.104473_bib0095","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s11926-012-0259-1","article-title":"Altered bone biology in psoriatic arthritis","volume":"14","author":"Rahimi","year":"2012","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.phrs.2019.104473_bib0100","first-page":"9","article-title":"Psoriatic arthritis: embracing pathogenetic and clinical heterogeneity?","volume":"34","author":"McInnes","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0105","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.38995","article-title":"Comparative genomic profiling of synovium versus skin lesions in psoriatic arthritis","volume":"67","author":"Belasco","year":"2015","journal-title":"Arthritis Rheumatol. Hoboken Nj"},{"key":"10.1016\/j.phrs.2019.104473_bib0110","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/1874312901105010133","article-title":"Synovial tissue response to treatment in psoriatic arthritis","volume":"5","author":"Codullo","year":"2011","journal-title":"Open Rheumatol. J."},{"key":"10.1016\/j.phrs.2019.104473_bib0115","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies","author":"McGonagle","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0120","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrrheum.2015.133","article-title":"Genetics of ankylosing spondylitis\u2014insights into pathogenesis","volume":"12","author":"Brown","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0125","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ajhg.2015.10.019","article-title":"Genome-wide association analysis of psoriatic arthritis and cutaneous psoriasis reveals differences in their genetic architecture","volume":"97","author":"Stuart","year":"2015","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.phrs.2019.104473_bib0130","doi-asserted-by":"crossref","first-page":"46","DOI":"10.3899\/jrheum.190119","article-title":"The genetics of psoriasis and psoriatic arthritis","volume":"95","author":"O\u2019Rielly","year":"2019","journal-title":"J. Rheumatol. Suppl."},{"key":"10.1016\/j.phrs.2019.104473_bib0135","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1136\/ard.2008.091389","article-title":"A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissue","volume":"68","author":"van Kuijk","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0140","doi-asserted-by":"crossref","first-page":"R148","DOI":"10.1186\/ar3090","article-title":"Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-\u03b1 blockade in the knee joint","volume":"12","author":"Fiocco","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2019.104473_bib0145","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3899\/jrheum.121162","article-title":"Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis","volume":"40","author":"Chandran","year":"2013","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0150","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1084\/jem.20071094","article-title":"Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses","volume":"204","author":"Zaba","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.phrs.2019.104473_bib0155","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1111\/exd.13304","article-title":"Langerhans cell markers CD1a and CD207 are the most rapidly responding genes in lesional psoriatic skin following adalimumab treatment","volume":"26","author":"Raaby","year":"2017","journal-title":"Exp. Dermatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0160","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bjd.12705","article-title":"The effect of adalimumab on key drivers in the pathogenesis of psoriasis","volume":"170","author":"Hendriks","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0165","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.ajpath.2013.04.021","article-title":"Inhibition of CCR7\/CCL19 Axis in lesional skin is a critical event for clinical remission induced by TNF blockade in patients with psoriasis","volume":"183","author":"Bos\u00e8","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.phrs.2019.104473_bib0170","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.jaad.2006.05.004","article-title":"Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients","volume":"55","author":"Malaviya","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0175","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1159\/000343290","article-title":"Randomized, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on lesional and nonlesional skin","volume":"225","author":"de Groot","year":"2012","journal-title":"Dermatology."},{"key":"10.1016\/j.phrs.2019.104473_bib0180","doi-asserted-by":"crossref","DOI":"10.1002\/art.40453","article-title":"Transcriptional profiling of synovial macrophages using minimally invasive ultrasound-guided synovial biopsies in rheumatoid arthritis","author":"Mandelin","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0185","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-018-1631-y","article-title":"Methods for high-dimensonal analysis of cells dissociated from cyropreserved synovial tissue","volume":"20","author":"Donlin","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2019.104473_bib0190","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1002\/art.40428","article-title":"Identification of three rheumatoid arthritis disease subtypes by machine learning integration of synovial histologic features and RNA sequencing data","volume":"70","author":"Orange","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0195","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02659-x","article-title":"Single-cell RNA-seq of rheumatoid arthritis synovial tissue using low-cost microfluidic instrumentation","volume":"9","author":"Stephenson","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2019.104473_bib0200","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-01771-2","article-title":"Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis","volume":"8","author":"Al-Mossawi","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2019.104473_bib0205","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/annrheumdis-2014-205417","article-title":"Discovery and confirmation of a protein biomarker panel with potential to predict response to biological therapy in psoriatic arthritis","volume":"75","author":"Ademowo","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0210","article-title":"A framework for multi-omic prediction of treatment response to biologic therapy for psoriasis","author":"Foulkes","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0215","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1136\/annrheumdis-2016-210424","article-title":"Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?","volume":"76","author":"Alivernini","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0220","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1136\/annrheumdis-2013-204229","article-title":"High incidence of disease recurrence after discontinuation of disease-modifying antirheumatic drug treatment in patients with psoriatic arthritis in remission","volume":"74","author":"Araujo","year":"2015","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0225","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0230","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2015-207507","article-title":"Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score","volume":"75","author":"Schoels","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0235","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1016\/S0140-6736(15)00347-5","article-title":"Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trial","volume":"386","author":"Coates","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.104473_bib0240","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/acr.20155","article-title":"Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data","volume":"62","author":"Coates","year":"2010","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.phrs.2019.104473_bib0245","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard.2011.150995","article-title":"A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis","volume":"71","author":"Ash","year":"2012","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0250","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1136\/annrheumdis-2015-208466","article-title":"Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"75","author":"Ramiro","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0255","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a Phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0260","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104473_bib0265","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","article-title":"Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Mease","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104473_bib0270","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","article-title":"T for, Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial","volume":"64","author":"Antoni","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0275","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/art.20967","article-title":"Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)","volume":"52","author":"Antoni","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104473_bib0280","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1002\/art.24403","article-title":"Golimumab, a new human tumor necrosis factor \u03b1 antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four\u2013week efficacy and safety results of a randomized, placebo-controlled study","volume":"60","author":"Kavanaugh","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104473_bib0285","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1136\/annrheumdis-2013-204902","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0290","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1002\/art.40226","article-title":"Safety and efficacy of intravenous golimumab in patients with active psoriatic arthritis","volume":"69","author":"Kavanaugh","year":"2017","journal-title":"Arthritis Rheumatol. Hoboken Nj"},{"key":"10.1016\/j.phrs.2019.104473_bib0295","first-page":"1040","article-title":"M.-570 S. Group, Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy","volume":"34","author":"Genovese","year":"2007","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0300","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.phrs.2019.104473_bib0305","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3899\/jrheum.091093","article-title":"Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis","volume":"37","author":"Mease","year":"2010","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0310","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1136\/ard.2006.057901","article-title":"Adalimumab improves joint\u2010related and skin\u2010related functional impairment in patients with psoriatic arthritis: patient\u2010reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial","volume":"66","author":"Gladman","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0315","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1136\/ard.2005.045658","article-title":"The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year","volume":"65","author":"Kavanaugh","year":"2006","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0320","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/art.22805","article-title":"Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2","volume":"56","author":"van der Heijde","year":"2007","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104473_bib0325","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/ard.2008.092767","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)","volume":"68","author":"Mease","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0330","first-page":"712","article-title":"Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept","volume":"33","author":"Mease","year":"2006","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0335","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD011535.pub2","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta\u2010analysis","author":"Sbidian","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.phrs.2019.104473_bib0340","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nrrheum.2017.188","article-title":"Enthesitis: from pathophysiology to treatment","volume":"13","author":"Schett","year":"2017","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0345","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3899\/jrheum.120254","article-title":"Treatment of psoriatic arthritis with tumor necrosis factor inhibitors: longer-term outcomes including enthesitis and dactylitis with golimumab treatment in the longterm extension of a randomized, placebo-controlled study (GO-REVEAL","volume":"89","author":"Kavanaugh","year":"2012","journal-title":"J. Rheumatol. Suppl."},{"key":"10.1016\/j.phrs.2019.104473_bib0350","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn\u2019s disease: a randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.phrs.2019.104473_bib0355","doi-asserted-by":"crossref","first-page":"c147","DOI":"10.1136\/bmj.c147","article-title":"Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial","volume":"340","author":"Sterry","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.phrs.2019.104473_bib0360","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-021447","article-title":"Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage on Rheumatic Diseases study on health care administrative databases","volume":"8","author":"Silvagni","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/j.phrs.2019.104473_bib0365","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1093\/rheumatology\/keu415","article-title":"Tumour necrosis factor inhibitor monotherapy vs combination with MTX in the treatment of PsA: a systematic review of the literature","volume":"54","author":"Behrens","year":"2015","journal-title":"Rheumatology"},{"key":"10.1016\/j.phrs.2019.104473_bib0370","article-title":"Efficacy of certolizumab pegol with and without concomitant use of disease-modifying anti-rheumatic drugs over 4 years in psoriatic arthritis patients: results from the RAPID-PsA randomized controlled trial","author":"Walsh","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0375","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3899\/jrheum.151290","article-title":"Comparison of etanercept monotherapy and combination therapy with methotrexate in psoriatic arthritis: results from 2 clinical trials","volume":"43","author":"Combe","year":"2016","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0380","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000606","article-title":"Design and rationale of the study of etanercept and methotrexate in combination or as monotherapy in subjects with psoriatic arthritis (SEAM-PsA)","volume":"4","author":"Mease","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.phrs.2019.104473_bib0385","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.40851","article-title":"Etanercept and methotrexate as monotherapy or in combination for psoriatic arthritis: primary results from a randomized, controlled phase III trial","volume":"71","author":"Mease","year":"2019","journal-title":"Arthritis Rheumatol. Hoboken Nj"},{"key":"10.1016\/j.phrs.2019.104473_bib0390","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/annrheumdis-2012-202347","article-title":"The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study","volume":"73","author":"Fagerli","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0395","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/ard.2007.073544","article-title":"Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register","volume":"67","author":"Kristensen","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0400","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2015-000181","article-title":"Comparative effectiveness of biologic monotherapy versus combination therapy for patients with psoriatic arthritis: results from the Corrona registry","volume":"1","author":"Mease","year":"2015","journal-title":"RMD Open"},{"key":"10.1016\/j.phrs.2019.104473_bib0405","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s40744-017-0070-6","article-title":"Comparative effectiveness of adalimumab versus secukinumab for the treatment of psoriatic arthritis: a matching-adjusted indirect comparison","volume":"4","author":"Strand","year":"2017","journal-title":"Rheumatol. Ther."},{"key":"10.1016\/j.phrs.2019.104473_bib0410","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40744-018-0106-6","article-title":"Secukinumab versus adalimumab for psoriatic arthritis: comparative effectiveness up to 48 weeks using a matching-adjusted indirect comparison","volume":"5","author":"Nash","year":"2018","journal-title":"Rheumatol. Ther."},{"key":"10.1016\/j.phrs.2019.104473_bib0415","series-title":"Efficacy of Secukinumab Compared to Adalimumab in Patients With Psoriatic Arthritis - Full Text View - ClinicalTrials.gOv","year":"2018"},{"key":"10.1016\/j.phrs.2019.104473_bib0420","series-title":"A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis - Tabular View - ClinicalTrials.gOv","year":"2019"},{"key":"10.1016\/j.phrs.2019.104473_bib0425","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1002\/art.30117","article-title":"Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti\u2013tumor necrosis factor \u03b1 therapy: results from the nationwide Danish DANBIO registry","volume":"63","author":"Glintborg","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104473_bib0430","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-018-1659-z","article-title":"Ten years of follow-up data in psoriatic arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway","volume":"20","author":"Haugeberg","year":"2018","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2019.104473_bib0435","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.semarthrit.2017.03.010","article-title":"Medication adherence and persistence over time with self-administered TNF-alpha inhibitors among young adult, middle-aged, and older patients with rheumatologic conditions","volume":"47","author":"Calip","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104473_bib0440","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000596","article-title":"Long-term persistence of TNF-inhibitor treatment in patients with psoriatic arthritis. Data from the British Society for Rheumatology Biologics Register","volume":"4","author":"Fagerli","year":"2018","journal-title":"RMD Open"},{"key":"10.1016\/j.phrs.2019.104473_bib0445","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1007\/s10067-017-3593-x","article-title":"Impact of prior biologic use on persistence of treatment in patients with psoriatic arthritis enrolled in the US Corrona registry","volume":"36","author":"Harrold","year":"2017","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0450","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1002\/acr.23333","article-title":"Impact of comorbidities on tumor necrosis factor inhibitor therapy in psoriatic arthritis: a population-based cohort study","volume":"70","author":"Ballegaard","year":"2018","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.phrs.2019.104473_bib0455","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1136\/annrheumdis-2015-208337","article-title":"European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update","volume":"75","author":"Gossec","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0460","doi-asserted-by":"crossref","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis: GRAPPA TREATMENT RECOMMENDATIONS FOR PsA","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0465","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nrrheum.2016.183","article-title":"Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations","volume":"12","author":"Gossec","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0470","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.3899\/jrheum.140878","article-title":"Systematic Review of Treatment Effectiveness and Outcome Measures for Enthesitis in Psoriatic Arthritis","volume":"41","author":"Orbai","year":"2014","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0475","article-title":"American college of Rheumatology\/National psoriasis foundation guideline for the treatment of psoriatic arthritis","volume":"2018","author":"Singh","year":"2018","journal-title":"Arthritis Care Res."},{"key":"10.1016\/j.phrs.2019.104473_bib0480","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1136\/annrheumdis-2018-214746","article-title":"Achieving remission in psoriatic arthritis by early initiation of TNF inhibition: a double-blind, randomised, placebo-controlled trial of golimumab plus methotrexate versus placebo plus methotrexate","volume":"78","author":"van Mens","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0485","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2017-211734","article-title":"Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force","volume":"77","author":"Smolen","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0490","doi-asserted-by":"crossref","DOI":"10.1007\/s11926-018-0781-x","article-title":"Novel concepts in psoriatic arthritis management: can we treat to target?","volume":"20","author":"Tucker","year":"2018","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.phrs.2019.104473_bib0495","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/art.40391","article-title":"Group for research and assessment of psoriasis and psoriatic Arthritis\/Outcome measures in rheumatology consensus-based recommendations and research agenda for use of composite measures and treatment targets in psoriatic arthritis","volume":"70","author":"Coates","year":"2018","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0500","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.semarthrit.2017.02.001","article-title":"Switching biologics in the treatment of psoriatic arthritis","volume":"47","author":"Merola","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104473_bib0505","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3899\/jrheum.150744","article-title":"Effectiveness and feasibility associated with switching to a second or third TNF inhibitor in patients with psoriatic arthritis: a cohort study from southern sweden","volume":"43","author":"Kristensen","year":"2016","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0510","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa1615977","article-title":"Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors","volume":"377","author":"Gladman","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104473_bib0515","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.104473_bib0520","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1056\/NEJMoa1412679","article-title":"Secukinumab inhibition of Interleukin-17A in patients with psoriatic arthritis","volume":"373","author":"Mease","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104473_bib0525","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1093\/rheumatology\/key182","article-title":"Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2","volume":"57","author":"Genovese","year":"2018","journal-title":"Rheumatol. Oxf. Engl."},{"key":"10.1016\/j.phrs.2019.104473_bib0530","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0535","first-page":"347","article-title":"One year in review 2018: novelties in the treatment of rheumatoid arthritis","volume":"36","author":"Bortoluzzi","year":"2018","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0540","article-title":"One year in review 2019: novelties in the treatment of rheumatoid arthritis","author":"Silvagni","year":"2019","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0545","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1007\/s10067-015-2886-1","article-title":"A feasibility study for a randomised controlled trial of treatment withdrawal in psoriatic arthritis (REmoval of treatment for patients in REmission in psoriatic ArThritis (RETREAT (F))","volume":"34","author":"Moverley","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0550","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000395","article-title":"Persistence of low disease activity after tumour necrosis factor inhibitor (TNFi) discontinuation in patients with psoriatic arthritis","volume":"3","author":"Huynh","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.phrs.2019.104473_bib0555","doi-asserted-by":"crossref","DOI":"10.1007\/s40265-018-0994-3","article-title":"Tapering and discontinuation of biologics in patients with psoriatic arthritis with low disease activity","author":"Ye","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.104473_bib0560","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s10067-015-2880-7","article-title":"Comparison between full and tapered dosages of biologic therapies in psoriatic arthritis patients: clinical and ultrasound assessment","volume":"34","author":"Janta","year":"2015","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0565","volume":"18","author":"B J","year":"2015","journal-title":"Value Health"},{"key":"10.1016\/j.phrs.2019.104473_bib0570","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1136\/annrheumdis-2016-209166","article-title":"The changing landscape of biosimilars in rheumatology","volume":"75","author":"D\u00f6rner","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0575","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1007\/s11926-016-0601-0","article-title":"Pharmacoeconomics of biosimilars: what is there to gain from them?","volume":"18","author":"Ara\u00fajo","year":"2016","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.phrs.2019.104473_bib0580","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13075-016-0981-6","article-title":"A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study","volume":"18","author":"Yoo","year":"2016","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2019.104473_bib0585","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1093\/rheumatology\/kex269","article-title":"52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis","volume":"56","author":"Emery","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.phrs.2019.104473_bib0590","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1136\/annrheumdis-2016-210459","article-title":"Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study","volume":"76","author":"Cohen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0595","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/bjd.15152","article-title":"The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. The originator product in patients with moderate-to-severe chronic plaque-type psoriasis","volume":"176","author":"Griffiths","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0600","article-title":"OP0220 Randomized, double-blind, global clinical trial to evaluate equivalence of CHS-1420 to adalimumab in patients with psoriasis and psoriatic arthritis","volume":"76","author":"O\u2019Dell","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0605","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/annrheumdis-2012-203091","article-title":"A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study","volume":"72","author":"Park","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0610","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.semarthrit.2015.04.002","article-title":"Clinical trial development for biosimilars","volume":"44","author":"Alten","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104473_bib0615","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1016\/S0140-6736(17)30068-5","article-title":"Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial","volume":"389","author":"J\u00f8rgensen","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.104473_bib0620","article-title":"Switching from adalimumab to Chs-1420: a randomized, double-blind global clinical trial in patients with psoriasis and psoriatic arthritis","author":"Hodge","year":"2017","journal-title":"ACR Meet. Abstr."},{"key":"10.1016\/j.phrs.2019.104473_bib0625","doi-asserted-by":"crossref","DOI":"10.1111\/apt.14997","article-title":"Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab","author":"Feagan","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.phrs.2019.104473_bib0630","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1007\/s12325-018-0742-9","article-title":"Non-medical switching from originator tumor necrosis factor inhibitors to their biosimilars: systematic review of randomized controlled trials and real-world studies","volume":"35","author":"Numan","year":"2018","journal-title":"Adv. Ther."},{"key":"10.1016\/j.phrs.2019.104473_bib0635","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1136\/annrheumdis-2016-210742","article-title":"A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry","volume":"76","author":"Glintborg","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0640","article-title":"To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry","author":"Glintborg","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0645","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3389\/fmed.2019.00144","article-title":"Major challenges in rheumatology: will we ever treat smarter, instead of just harder?","volume":"6","author":"Rom\u00e3o","year":"2019","journal-title":"Front. Med."},{"key":"10.1016\/j.phrs.2019.104473_bib0650","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.208","article-title":"The nocebo effect of drugs","volume":"4","author":"Plan\u00e8s","year":"2016","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.phrs.2019.104473_bib0655","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40744-017-0085-z","article-title":"Treatment outcomes with biosimilars: Be aware of the nocebo effect","volume":"4","author":"Rezk","year":"2017","journal-title":"Rheumatol. Ther."},{"key":"10.1016\/j.phrs.2019.104473_bib0660","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2019-000900","article-title":"Era of biosimilars in rheumatology: reshaping the healthcare environment","volume":"5","author":"Smolen","year":"2019","journal-title":"RMD Open"},{"key":"10.1016\/j.phrs.2019.104473_bib0665","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1136\/annrheumdis-2016-210708","article-title":"Safety of synthetic and biological DMARDs: a systematic literature review informing the 2016 update of the EULAR recommendations for management of rheumatoid arthritis","volume":"76","author":"Ramiro","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0670","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1080\/14740338.2016.1240783","article-title":"Risk of infections using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Minozzi","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.phrs.2019.104473_bib0675","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.2174\/0929867322666150209160701","article-title":"Tumor necrosis factor blocking therapy and congestive heart failure in patients with inflammatory rheumatic disorders: a systematic review","volume":"22","author":"Heslinga","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.phrs.2019.104473_bib0680","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12016-016-8560-9","article-title":"The effect of TNF inhibitors on cardiovascular events in psoriasis and psoriatic arthritis: an updated meta-analysis","volume":"51","author":"Yang","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.phrs.2019.104473_bib0685","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1080\/14740338.2016.1238458","article-title":"Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis","volume":"15","author":"Bonovas","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.phrs.2019.104473_bib0690","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key241","article-title":"Malignancy and mortality rates in patients with severe psoriatic arthritis requiring tumour-necrosis factor alpha inhibition: results from the British Society for Rheumatology Biologics Register","author":"Fagerli","year":"2019","journal-title":"Rheumatology"},{"key":"10.1016\/j.phrs.2019.104473_bib0695","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.semarthrit.2017.02.007","article-title":"Risks of malignancies related to tofacitinib and biological drugs in rheumatoid arthritis: systematic review, meta-analysis, and network meta-analysis","volume":"47","author":"Maneiro","year":"2017","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104473_bib0700","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/14740338.2018.1400530","article-title":"Skin cancer associated with commonly prescribed drugs: tumor necrosis factor alpha inhibitors (TNF-\u03b1Is), angiotensin-receptor blockers (ARBs), phosphodiesterase type 5 inhibitors (PDE5Is) and statins -weighing the evidence","volume":"17","author":"Nardone","year":"2018","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.phrs.2019.104473_bib0705","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jaad.2016.09.047","article-title":"The risk of melanoma and hematologic cancers in patients with psoriasis","volume":"76","author":"Reddy","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0710","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1001\/jamadermatol.2015.4847","article-title":"The risk of Cancer in patients with psoriasis: a population-based cohort study in the health improvement network","volume":"152","author":"Fuxench","year":"2016","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0715","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1136\/annrheumdis-2016-209285","article-title":"Risk of invasive melanoma in patients with rheumatoid arthritis treated with biologics: results from a collaborative project of 11 European biologic registers","volume":"76","author":"Mercer","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0720","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jaad.2016.08.012","article-title":"Tumor necrosis factor-\u03b1 inhibitor-induced psoriasis: systematic review of clinical features, histopathological findings, and management experience","volume":"76","author":"Brown","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0725","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s40257-017-0296-7","article-title":"Clinical Signs, Pathophysiology and Management of Cutaneous Side Effects of Anti-Tumor Necrosis Factor Agents","volume":"18","author":"Segaert","year":"2017","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0730","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/j.semarthrit.2013.10.007","article-title":"Non-length-dependent and length-dependent small-fiber neuropathies associated with tumor necrosis factor (TNF)-inhibitor therapy in patients with rheumatoid arthritis: expanding the spectrum of neurological disease associated with TNF-inhibitors","volume":"43","author":"Birnbaum","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104473_bib0735","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/rheumatology\/kes375","article-title":"Pattern of demyelination occurring during anti-TNF-\u03b1 therapy: a French national survey","volume":"52","author":"Seror","year":"2013","journal-title":"Rheumatology"},{"key":"10.1016\/j.phrs.2019.104473_bib0740","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1007\/s10067-017-3884-2","article-title":"Diverse patterns of anti-TNF-\u03b1-induced lupus: case series and review of the literature","volume":"37","author":"Shovman","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0745","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13317-013-0057-4","article-title":"The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications","volume":"5","author":"Marinoni","year":"2014","journal-title":"Auto Immun. Highlights"},{"key":"10.1016\/j.phrs.2019.104473_bib0750","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1365-2567.2011.03465.x","article-title":"The interleukin-17 cytokine family: critical players in host defence and inflammatory diseases","volume":"134","author":"Pappu","year":"2011","journal-title":"Immunology"},{"key":"10.1016\/j.phrs.2019.104473_bib0755","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1038\/nm.2854","article-title":"Primed for inflammation: enthesis-resident T cells","volume":"18","author":"Lories","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2019.104473_bib0760","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000284","article-title":"Update on interleukin-17: a role in the pathogenesis of inflammatory arthritis and implication for clinical practice","volume":"3","author":"Miossec","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.phrs.2019.104473_bib0765","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1126\/science.1200439","article-title":"Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity","volume":"332","author":"Puel","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.phrs.2019.104473_bib0770","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jaad.2013.12.036","article-title":"Interleukin 17A: toward a new understanding of psoriasis pathogenesis","volume":"71","author":"Lynde","year":"2014","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0775","article-title":"Histologic evidence that mast cells contribute to local tissue inflammation in peripheral spondyloarthritis by regulating interleukin-17A content","author":"Chen","year":"2018","journal-title":"Rheumatology"},{"key":"10.1016\/j.phrs.2019.104473_bib0780","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1189\/jlb.3HI1215-542R","article-title":"Human mast cells capture, store, and release bioactive, exogenous IL-17A","volume":"100","author":"Noordenbos","year":"2016","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.phrs.2019.104473_bib0785","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1056\/NEJMra0707449","article-title":"Interleukin-17 and type 17 helper T cells","volume":"361","author":"Miossec","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104473_bib0790","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/art.38291","article-title":"Review: the interleukin-23\/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond","volume":"66","author":"Smith","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0795","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/nm.2817","article-title":"IL-23 induces spondyloarthropathy by acting on ROR-gammat+ CD3+CD4-CD8- entheseal resident T cells","volume":"18","author":"Sherlock","year":"2012","journal-title":"Nat. Med."},{"key":"10.1016\/j.phrs.2019.104473_bib0800","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/s41584-018-0044-2","article-title":"IL-17 in the immunopathogenesis of spondyloarthritis","volume":"14","author":"Taams","year":"2018","journal-title":"Nat. Rev. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0805","article-title":"Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis","volume":"6","author":"Bowes","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2019.104473_bib0810","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.1002\/art.24128","article-title":"Investigation of association of the IL12B and IL23R genes with psoriatic arthritis","volume":"58","author":"Filer","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104473_bib0815","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1136\/ard.2011.150102","article-title":"Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis","volume":"70","author":"Bowes","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0820","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/art.37936","article-title":"Combinatorial control of Th17 and Th1 cell functions by genetic variations in genes associated with the Interleukin-23 signaling pathway in spondyloarthritis","volume":"65","author":"Coffre","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104473_bib0825","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/ng.688","article-title":"Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis","volume":"42","author":"H\u00fcffmeier","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.phrs.2019.104473_bib0830","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1056\/NEJMoa0810652","article-title":"Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis","volume":"362","author":"Griffiths","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104473_bib0835","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0140-6736(09)60140-9","article-title":"Ustekinumab, a human interleukin 12\/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial","volume":"373","author":"Gottlieb","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.104473_bib0840","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1016\/S0140-6736(13)60594-2","article-title":"Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial","volume":"382","author":"McInnes","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.104473_bib0845","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0850","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1080\/14740338.2017.1323864","article-title":"The safety of ustekinumab for the treatment of psoriatic arthritis","volume":"16","author":"L\u00f3pez-Ferrer","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.phrs.2019.104473_bib0855","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10067-018-3989-2","article-title":"Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE)","volume":"37","author":"Iannone","year":"2018","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0860","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1016\/S0140-6736(18)31217-0","article-title":"Psoriatic arthritis: novel targets add to a therapeutic renaissance","volume":"391","author":"Nash","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.104473_bib0865","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0870","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0875","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1056\/NEJMoa1607017","article-title":"Risankizumab versus ustekinumab for moderate-to-Severe plaque psoriasis","volume":"376","author":"Papp","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104473_bib0880","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"Reich","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0885","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s13555-017-0187-0","article-title":"Guselkumab for the treatment of psoriasis: a review of phase III trials","volume":"7","author":"Nakamura","year":"2017","journal-title":"Dermatol. Ther. Heidelb."},{"key":"10.1016\/j.phrs.2019.104473_bib0890","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1016\/S0140-6736(18)30952-8","article-title":"Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study","volume":"391","author":"Deodhar","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.104473_bib0895","first-page":"1550","article-title":"Efficacy and safety results from a phase 2 trial of risankizumab, a selective IL-23p19 inhibitor,in patients with active psoriatic arthritis (abstract)","volume":"76","author":"Mease","year":"2017","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0900","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1136\/annrheumdis-2016-209709","volume":"76","author":"Mease","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0905","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1016\/S0140-6736(17)31429-0","article-title":"Ixekizumab for the treatment of patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors: results from the 24-week randomised, double-blind, placebo-controlled period of the SPIRIT-P2 phase 3 trial","volume":"389","author":"Nash","year":"2017","journal-title":"Lancet"},{"issue":"Suppl 2","key":"10.1016\/j.phrs.2019.104473_bib0910","doi-asserted-by":"crossref","first-page":"ii116","DOI":"10.1136\/annrheumdis-2012-202371","article-title":"Effect of IL-17A blockade with secukinumab in autoimmune diseases","volume":"72","author":"Patel","year":"2013","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0915","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an Interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104473_bib0920","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2013results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104473_bib0925","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Thaci","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0930","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.phrs.2019.104473_bib0935","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/JIR.S100940","article-title":"Generation and characterization of ixekizumab, a humanized monoclonal antibody that neutralizes interleukin-17A","volume":"9","author":"Liu","year":"2016","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.phrs.2019.104473_bib0940","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s40265-016-0579-y","article-title":"Ixekizumab: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.phrs.2019.104473_bib0945","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1136\/annrheumdis-2017-212127","article-title":"Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation","volume":"77","author":"Glatt","year":"2018","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0950","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1315231","article-title":"Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis","volume":"370","author":"Mease","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104473_bib0955","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/annrheumdis-2016-210724","article-title":"Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis","volume":"76","author":"Mease","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib0960","doi-asserted-by":"crossref","first-page":"R107","DOI":"10.1186\/ar3041","article-title":"Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis","volume":"12","author":"McCann","year":"2010","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.phrs.2019.104473_bib0965","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/j.1476-5381.2009.00559.x","article-title":"Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis","volume":"159","author":"Schafer","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104473_bib0970","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2018.00287","article-title":"\u201cDo we know jack\u201d about JAK? A closer look at JAK\/STAT signaling pathway","volume":"8","author":"Bousoik","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2019.104473_bib0975","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1080\/13543776.2016.1192129","article-title":"Small molecules and antibodies for the treatment of psoriasis: a patent review (2010-2015)","volume":"26","author":"Chiricozzi","year":"2016","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.phrs.2019.104473_bib0980","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s11926-014-0443-6","article-title":"Novel treatments with small molecules in psoriatic arthritis","volume":"16","author":"Hansen","year":"2014","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.phrs.2019.104473_bib0985","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1007\/s40257-016-0179-3","article-title":"Novel oral therapies for psoriasis and psoriatic arthritis","volume":"17","author":"Yiu","year":"2016","journal-title":"Am. J. Clin. Dermatol."},{"key":"10.1016\/j.phrs.2019.104473_bib0990","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1310\/hpj4908-752","article-title":"Apremilast","volume":"49","author":"Cada","year":"2014","journal-title":"Hosp. Pharm."},{"key":"10.1016\/j.phrs.2019.104473_bib0995","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","article-title":"Apremilast mechanism of action and application to psoriasis and psoriatic arthritis","volume":"83","author":"Schafer","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.phrs.2019.104473_bib1000","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1152\/physrev.00021.2003","article-title":"Localized effects of cAMP mediated by distinct routes of protein kinase A","volume":"84","author":"Tasken","year":"2004","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.phrs.2019.104473_bib1005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj20021698","article-title":"PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization","volume":"370","author":"Houslay","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.phrs.2019.104473_bib1010","doi-asserted-by":"crossref","first-page":"3156","DOI":"10.1002\/art.34627","article-title":"Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study","volume":"64","author":"Schett","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2019.104473_bib1015","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.3899\/jrheum.121200","article-title":"Patient-reported Health-related Quality of Life with apremilast for psoriatic arthritis: a phase II, randomized, controlled study","volume":"40","author":"Strand","year":"2013","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib1020","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3899\/jrheum.151376","article-title":"A phase III, randomized, controlled trial of apremilast in patients with psoriatic arthritis: results of the PALACE 2 trial","volume":"43","author":"Cutolo","year":"2016","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib1025","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib1030","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3899\/jrheum.140647","article-title":"Longterm (52-week) results of a phase III randomized, controlled trial of apremilast in patients with psoriatic arthritis","volume":"42","author":"Kavanaugh","year":"2015","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.phrs.2019.104473_bib1035","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib1040","doi-asserted-by":"crossref","DOI":"10.1093\/rheumatology\/key032","article-title":"Apremilast monotherapy in DMARD-naive psoriatic arthritis patients: results of the randomized, placebo-controlled PALACE 4 trial","author":"Wells","year":"2018","journal-title":"Rheumatol. Oxf."},{"key":"10.1016\/j.phrs.2019.104473_bib1045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12026-013-8481-0","article-title":"JAK\/STAT\/PKC\u03b4 molecular pathways in synovial fluid T lymphocytes reflect the in vivo T helper-17 expansion in psoriatic arthritis","volume":"58","author":"Fiocco","year":"2014","journal-title":"Immunol. Res."},{"key":"10.1016\/j.phrs.2019.104473_bib1050","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/annrheumdis-2014-207201","article-title":"Tofacitinib regulates synovial inflammation in psoriatic arthritis, inhibiting STAT activation and induction of negative feedback inhibitors","volume":"75","author":"Gao","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.phrs.2019.104473_bib1055","series-title":"Tofacitinib for Psoriatic Arthritis (PsA) Is Now Approved by the European Commission. - PubMed - NCBI","year":"2018"},{"key":"10.1016\/j.phrs.2019.104473_bib1060","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1056\/NEJMoa1615975","article-title":"Tofacitinib or adalimumab versus placebo for psoriatic arthritis","volume":"377","author":"Mease","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104473_bib1065","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1056\/NEJMe1709907","article-title":"JAK inhibitors taking on psoriatic arthritis","volume":"377","author":"Colbert","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2019.104473_bib1070","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1111\/bjd.14403","article-title":"A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1\/JAK2 inhibitor, in patients with moderate-to-severe psoriasis","volume":"174","author":"Papp","year":"2016","journal-title":"Br. J. Dermatol."},{"key":"10.1016\/j.phrs.2019.104473_bib1075","year":"2018"},{"key":"10.1016\/j.phrs.2019.104473_bib1080","series-title":"A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-biologic Disease Modifying Anti-rheumatic Drug - Full Text View - ClinicalTrials.gOv","year":"2018"},{"key":"10.1016\/j.phrs.2019.104473_bib1085","article-title":"Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in psoriatic arthritis","author":"Miyagawa","year":"2018","journal-title":"Rheumatology"}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819310643?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661819310643?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T22:01:52Z","timestamp":1760911312000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661819310643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11]]},"references-count":217,"alternative-id":["S1043661819310643"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104473","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biological and synthetic target DMARDs in psoriatic arthritis","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2019.104473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104473"}}